1
|
Fu Q, Figuera-Losada M, Ploplis VA, Cnudde S, Geiger JH, Prorok M, Castellino FJ. The lack of binding of VEK-30, an internal peptide from the group A streptococcal M-like protein, PAM, to murine plasminogen is due to two amino acid replacements in the plasminogen kringle-2 domain. J Biol Chem 2007; 283:1580-1587. [PMID: 18039665 DOI: 10.1074/jbc.m705063200] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
VEK-30, a 30-amino acid internal peptide present within a streptococcal M-like plasminogen (Pg)-binding protein (PAM) from Gram-positive group-A streptococci (GAS), represents an epitope within PAM that shows high affinity for the lysine binding site (LBS) of the kringle-2 (K2) domain of human (h)Pg. VEK-30 does not interact with this same region of mouse (m)Pg, despite the high conservation of the mK2- and hK2-LBS. To identify the molecular basis for the species specificity of this interaction, hPg and mPg variants were generated, including an hPg chimera with the mK2 sequence and an mPg chimera containing the hK2 sequence. The binding of synthetic VEK-30 to these variants was studied by surface plasmon resonance. The data revealed that, in otherwise intact Pg, the species specificity of VEK-30 binding in these two cases is entirely dictated by two K2 residues that are different between hPg and mPg, namely, Arg-220 of hPg, which is a Gly in mPg, and Leu-222 of hPg, which is a Pro in mPg, neither of which are members of the canonical K2-LBS. Neither the activation of hPg, nor the enzymatic activity of its activated product, plasmin (hPm), are compromised by replacing these two amino acids by their murine counterparts. It is also demonstrated that hPg is more susceptible to activation to hPm after complexation with VEK-30 and that this property is greatly reduced as a result of the R220G and L222P replacements in hPg. These mechanisms for accumulation of protease activity on GAS likely contribute to the virulence of PAM(+)-GAS strains and identify targets for new therapeutic interventions.
Collapse
Affiliation(s)
- Qihua Fu
- W. M. Keck Center for Transgene Research and the Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Mariana Figuera-Losada
- W. M. Keck Center for Transgene Research and the Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Victoria A Ploplis
- W. M. Keck Center for Transgene Research and the Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Sara Cnudde
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824
| | - James H Geiger
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824
| | - Mary Prorok
- W. M. Keck Center for Transgene Research and the Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Francis J Castellino
- W. M. Keck Center for Transgene Research and the Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556.
| |
Collapse
|
2
|
Alfonsi-Hourdin S, Longchamp S, Gallet O, Nigretto JM. Electrochemical processing of fibrinogen modified-graphite surfaces: Effect on plasmin generation from adsorbed plasminogen. Biomaterials 2006; 27:52-60. [PMID: 16029886 DOI: 10.1016/j.biomaterials.2005.05.092] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2005] [Accepted: 05/27/2005] [Indexed: 11/26/2022]
Abstract
With the aim to improve the fibrinolytic properties of carbons by different biological and electrochemical treatments, we modified graphite surfaces by fibrinogen adsorption and subsequent application of various constant potentials before submitting them to plasminogen adsorption. First, we verified that plasminogen (purified or present in human plasma) could adsorb onto these modified surfaces and that adsorbed plasminogen could be converted by t-PA (the principal physiological activator of plasminogen) to adsorbed plasmin. The catalytic properties of the generated enzyme were characterized in assay solutions containing t-PA, fibrinogen and the chromogenic substrate S-2403 (pyroGlu-Phe-Lys-p-nitroaniline, HCl). Experiments showed that the application of electrical potentials to the fibrinogen coating could indirectly affect the properties of the material. In the case of anodic potentials, the amidolytic activity of the generated plasmin was significantly enhanced. Especially, this activity was 10 times higher at a particular potential value.
Collapse
|
3
|
Dominguez M, Montes R, Páramo JA, Anglés-Cano E. Bivalency of plasminogen monoclonal antibodies is required for plasminogen bridging to fibrin and enhanced plasmin formation. BIOCHIMICA ET BIOPHYSICA ACTA 2002; 1598:165-76. [PMID: 12147357 DOI: 10.1016/s0167-4838(02)00364-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Binding of plasminogen to fibrin and cell surfaces is essential for fibrinolysis and pericellular proteolysis. We used surface plasmon resonance and enzyme kinetic analyses to study the effect of two mAbs (A10.2, CPL15) on plasminogen binding and activation at fibrin surfaces. A10.2 is directed against the lysine-binding site (LBS) of kringle 4, whereas CPL15 recognises a region in kringle 1 outside the LBS. In the presence of CPL15 and A10.2 mAbs, binding of plasminogen (K(d)=1.16+/-0.22 micromol/l) to fibrin was characterised by a mAb concentration-dependent bell-shaped isotherm. A progressive increase in the concentration of mAbs at the surface was also detected, and reached a plateau corresponding to the maximum of plasminogen bound. These data indicated that at low mAb concentration, bivalent plasminogen-mAb-plasminogen ternary complexes are formed, whereas at high mAb concentration, a progressive shift to monovalent plasminogen-mAb binary complexes is observed. Plasmin formation in the presence of mAbs followed a similar bell-shaped profile. Monovalent Fab fragments of mAb A10.2 showed no effect on the binding of plasminogen, confirming the notion that a bivalent mAb interaction is essential to increase plasminogen binding and activation at the surface of fibrin.
Collapse
Affiliation(s)
- Miguel Dominguez
- Plasminogen Activation in Cardiovascular Remodelling, Institut National de la Santé et de la Recherche Médicale, INSERM U460, UFR de Médecine Xavier Bichat, 16 rue Henri Huchard-BP 416, Paris, France
| | | | | | | |
Collapse
|
4
|
|
5
|
Soulat T, Dominguez M, Martin I, Anglés-Cano E. Immobilisation of monocytes to a solid support: a model for the study of ligand-binding interactions and plasminogen activation at the cell surface. Thromb Res 2000; 96:473-80. [PMID: 10632471 DOI: 10.1016/s0049-3848(99)00141-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The functional and immunological identification of receptors expressed by cells of the monocyte/ macrophage lineage may be facilitated with the use of immobilised cells. A procedure is described here for attaching human blood monocytes, alveolar macrophages, and THP-1 cells to a solid support activated with polymerised glutaraldehyde. Homogeneous monolayers visualised by optical microscopy were obtained at predefined input cell densities and were quantitatively characterised with the use of 125I-plasminogen (35000+/-2772 cells/well at approximately 76000 cells/50 microL) and 125I-pro-urokinase (39000+/-3839 cells/well at approximately 86000 cells/50 microL). The cells remained stably attached during washing and incubation procedures in ligand-binding studies. The functionality of membrane receptors and acceptors of the immobilised cells for a number of ligands was verified. Parameters of the interaction of plasminogen, urokinase, and human immunoglobulin G with their corresponding receptors were similar to those previously reported using cells in suspension. The functionality of bound ligands, such as urokinase and plasminogen, was verified by measuring their ability to generate plasmin. We conclude that immobilised monocytes/macrophages are a useful tool for studying ligand interactions with membrane proteins and for the realisation of plasminogen activation studies at the surface of the cell membrane.
Collapse
Affiliation(s)
- T Soulat
- INSERM U.143 Hémostase-Biologie Vasculaire, Hôpital de Bicêtre, Paris, France
| | | | | | | |
Collapse
|
6
|
Credo RB, Burke SE. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. J Vasc Interv Radiol 1995; 6:8S-18S. [PMID: 8770836 DOI: 10.1016/s1051-0443(95)71242-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The purpose of this review is to provide a biochemical characterization of recombinant prourokinase (r-ProUK [ABT-187]), including a description of its clot-specific fibrinolytic mechanism. In addition, the preclinical data will be briefly reviewed, demonstrating the efficacy of r-ProUK as a potent therapeutic plasminogen activator. r-ProUK was purified to homogeneity from the culture medium of SP2/0 mouse hybridoma cells. The fibrinolytic potency of r-ProUK was characterized by both in vitro clot lysis experiments in human plasma and a canine femoral artery thrombosis model. In the in vitro clot lysis system, with use of clots prepared from fresh frozen human plasma, r-ProUK exhibits a lag phase to the onset of lysis and a concentration-dependent threshold effect due to the presence of the inhibitors alpha 2-antiplasmin and plasminogen activator inhibitor (PAI-1). Effective clot lysis can be achieved without degradation of the fibrinogen in the surrounding plasma. Over a dose range of 50,000-220,000 IU, the canine femoral artery thrombosis model shows a dose-dependent relationship for r-ProUK and effective clot lysis. The lytic activity of r-ProUK is significantly enhanced in this model by the concomitant administration of heparin as an adjunctive agent for thrombolytic treatment. Fibrinogen, plasminogen, and alpha 2-antiplasmin levels in the systemic circulation were unaltered during the 30-minute infusion period and a 4-hour observation period, in which 85% lysis was achieved with r-ProUK (100,000 IU) and heparin. Moreover, restoration of blood flow in the previously fully occluded femoral artery was achieved within minutes of the start of the r-ProUK infusion. The experimental findings presented here are consistent with the clot-specific fibrinolytic mechanism of r-ProUK. Effective clot lysis can be achieved without alteration of the systemic coagulation and fibrinolytic parameters.
Collapse
Affiliation(s)
- R B Credo
- Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Ill 60064-3500, USA
| | | |
Collapse
|
7
|
Abstract
The fibrinolytic system comprises an inactive proenzyme, plasminogen, that is converted by plasminogen activators to the active enzyme, plasmin, which degrades fibrin. Two immunologically distinct plasminogen activators (PA) have been identified: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). t-PA mediated plasminogen activation is mainly involved in the dissolution of fibrin in the circulation, whereas u-PA mediated plasminogen activation mainly plays a role in pericellular proteolysis. Plasminogen activation is regulated by specific molecular interactions between its main components, such as binding of plasminogen and t-PA to fibrin, or to specific cellular receptors resulting in enhanced plasminogen activation, inhibition of t-PA and u-PA by plasminogen activator inhibitors (PAI) and inhibition of plasmin by alpha 2-antiplasmin. Controlled synthesis and release of PAs and PAIs primarily from endothelial cells also contributes to the regulation of physiological fibrinolysis. The lysine binding sites situated in the kringle structures of plasminogen play a crucial role in the regulation of fibrinolysis by modulating its binding to fibrin and to cell surfaces, and by controlling the inhibition rate of plasmin by alpha 2-antiplasmin.
Collapse
Affiliation(s)
- H R Lijnen
- Center for Molecular and Vascular Biology, K.U. Leuven, Belgium
| | | |
Collapse
|
8
|
Affiliation(s)
- H R Lijnen
- Centre for Molecular and Vascular Biology, University of Leuven, Belgium
| | | | | | | | | | | | | |
Collapse
|
9
|
Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993. [DOI: 10.1016/s0021-9258(17)46663-4] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
10
|
Fleury V, Loyau S, Lijnen HR, Nieuwenhuizen W, Anglés-Cano E. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. EUROPEAN JOURNAL OF BIOCHEMISTRY 1993; 216:549-56. [PMID: 8375393 DOI: 10.1111/j.1432-1033.1993.tb18173.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
A well characterized model of an intact and a degraded surface of fibrin that represents the states of fibrin during the initiation and the progression of fibrinolysis was used to quantitatively characterize the molecular interplay between tissue-type plasminogen activator (t-PA), plasminogen and fibrin. The molecular assembly of t-PA and plasminogen on these surfaces was investigated using combinations of proteins that preclude complications due to side reactions caused by generated plasmin: native plasminogen with di-isopropylphosphofluoridate-inactivated t-PA, and a recombinant human plasminogen with the active-site Ser741 mutagenized to Ala which renders the catalytic site inactive. Under these conditions, neither the affinity nor the maximal number of binding sites for plasminogen were modified by the presence of t-PA, indicating that binding sites for plasminogen pre-exist in intact fibrin and are not dependent on the presence of t-PA. In contrast, when plasminogen activation is allowed, increasing binding of plasminogen to the progressively degraded fibrin surface is directly correlated (r = 0.98) to the appearance of the fibrin E-fragment as shown using a monoclonal antibody (FDP-14) that has its epitope in the E domain of fibrin. t-PA was shown to bind with a high affinity to both the intact (Kd = 3.3 +/- 0.6 nM) and the degraded surface of fibrin (Kd = 1.2 +/- 0.4 nM). Binding of t-PA to carboxy-terminal lysine residues of degraded fibrin was shown to be efficiently competed by physiological concentrations of plasminogen (2 microM), indicating that the affinity of t-PA for these residues was lower than that of plasminogen (Kd = 0.66 +/- 0.22 microM) and unrelated to the high affinity of t-PA for specific binding sites on intact fibrin. These data confirm and establish that the generation of carboxy-terminal lysine residues on fibrin during ongoing fibrinolysis, and the binding of plasminogen to these sites, is an important pathway in the acceleration of clot dissolution.
Collapse
Affiliation(s)
- V Fleury
- Institut National de la Santé et de la Recherche Médicale, Centre Hospitalo-Universitaire of Bicêtre, France
| | | | | | | | | |
Collapse
|